Implications of Ongoing Circulating Vaccine Spike Protein

Research focused on spike protein circulation post-vaccination and antibody response. • 1:09

Dr. Carlo Brogna and George M. Gash leading the discussion on their findings. • 2:03

Study aimed to understand spike protein persistence and impact on immunity. • 3:07

Importance of determining spike protein half-life for vaccine effectiveness. • 5:33

Ongoing research to further investigate spike protein presence after six months. • 7:08

Initial results showed spike protein detected in 50% of vaccinated individuals. • 7:18

Discussion on potential implications of spike protein presence independent of antibody levels. • 7:33

Challenges of extrapolating findings from small-scale study with 20 participants. • 7:42

Study focused on medical doctors administering mRNA vaccines • 8:39

Challenges in recruiting participants due to low vaccination rates in Italy • 8:57

Method developed towards the end of the pandemic limiting participation to 20 doctors • 9:38

Differentiating spike protein from vaccine vs infection using proteomic methods • 11:13

Some individuals had circulating spike protein without generating antibodies • 13:08

Duration of circulating spike protein studied up to six months post double mRNA dose • 14:55

Mechanisms of circulating spike protein discussed with three potential ideas • 15:33

Testing hypotheses on spike protein integration, production, and bacterial involvement. • 15:41

Plan to reevaluate spike protein presence in cells after two years. • 16:32

Investigating bacterial production of spike protein post-vaccination. • 17:11

Consideration of extracellular vesicles containing spike protein affecting antibody response. • 18:23

Exploration of potential bacterial role in spike protein production and immune response. • 19:28

Observation of disbiosis similarities in vaccine-injured and Long Covid patients. • 21:45

Need for further research on mechanisms linking bacteria, spike protein, and immune response. • 22:11

Patients treated with specific antibiotics show no long covid symptoms. • 23:01

Microbiome may play a crucial role in preventing long covid conditions. • 23:23

Concerns raised about the misinformation regarding persistent spike protein production. • 26:01

Research suggests presence of spike protein fragments in gut epithelium post-infection. • 27:33

Speculation on the source of prolonged spike protein production, possibly immune cells or bacteria. • 28:13

Identification of spike protein sequences in the gut epithelium post-degradation. • 29:08

Detection of specific epitope indicates ongoing Spike protein production post-vaccination. • 29:25

Presence of Spike protein in serum suggests deposition in cells, posing a warning sign. • 29:53

Free-floating Spike protein in blood implies higher amount deposited in cells. • 34:18

Spike protein has high affinity to fuse with cell membranes and receptors. • 34:50

Hypothesis involving line one and retroviruses may be linked to presence of Spike protein in human cells. • 35:04

Spike protein integration into DNA and SV40 promoter assisting integration into cells. • 35:12

Spike protein can cause harm in the body, leading to various health issues. • 36:02

Presence of circulating spike protein may drive autoimmune diseases over time. • 38:29

Autoimmune state development in long-haulers with prolonged exposure to spike proteins. • 39:37

Autoantibodies attacking own cells, especially in the central nervous system. • 39:53

Some individuals experiencing autoimmune-driven symptoms like ALS, leading to unpleasant outcomes. • 40:07

Challenges in addressing autoimmune issues arising from prolonged exposure to spike protein. • 40:24

Importance of understanding and addressing consequences of spike protein circulation. • 40:35

Identification of at-risk individuals is challenging due to lack of clear markers for long COVID and vaccine injuries. • 41:07

Markers such as TGF beta and neurological proteins like GFAP and amyloid beta 40/42 ratios are prevalent in long haulers. • 42:25

Microclotting observed under fluorescent microscopy is becoming increasingly common, indicating a serious issue. • 44:13

The combination of a highly infectious variant triggering an autoimmune response poses a significant challenge. • 45:26

Primary pathophysiology of microclotting needs to be understood to address the issue effectively. • 46:07

Caution advised against using triple anticoagulation without a clear understanding of the underlying mechanisms. • 46:13

Flying blind in addressing microclotting without a complete understanding of the situation. • 46:39

Spike protein in endothelial cells leads to inflammation and coagulation cascade. • 46:58

Removing spike protein from cells is crucial for recovery. • 47:32

Differentiating between productive and unproductive persistence of spike protein. • 48:50

Need to bind and remove spike protein safely to prevent further harm. • 50:03

Complexity of the issue requires scientific community’s attention for solutions. • 50:41

Focus should be on mitigating impact and protecting individuals from severe outcomes. • 51:39

Urgent need for medical authorities to acknowledge and act on groundbreaking research findings. • 52:22

Lack of understanding in hospitals regarding effective treatments for COVID-19 patients. • 53:09

Importance of utilizing H1 H2 blocker and Montoluucas to avoid patients being put on respirators. • 53:34

Criticism towards the medical community for not heeding advice from experts with proven success in treating COVID-19. • 53:42

Call for a reevaluation of interventions and strategies to control the spread of the virus. • 54:13

Acknowledgment of the challenging times and the necessity to make a difference in combating the pandemic. • 54:47

Appreciation for research and developments aimed at helping people during the crisis. • 55:10

Wishing Merry Christmas to all viewers and expressing gratitude for their support. • 55:16

Closure of the discussion with thanks and well wishes. • 55:24